Adma Biologics (ADMA) Current Assets (2011 - 2025)

Adma Biologics has reported Current Assets for 14 years, with the latest figure at $466.5 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets rose 40.77% year-over-year to $466.5 million; the trailing twelve-month figure through Dec 2025 stood at $466.5 million (up 40.77% YoY), and the FY2025 full-year result was $466.5 million, up 40.77% from the prior year.
• Current Assets for Q4 2025 stood at $466.5 million, up from $402.7 million in the prior quarter.
• The five-year high for Current Assets was $466.5 million in Q4 2025, with the low at $171.4 million in Q2 2021.
• Historically, Current Assets has averaged $280.0 million across 5 years, with a median of $268.3 million in 2022.
• Annual changes were most pronounced in 2023 — Current Assets retreated 4.95% — and 2025, when it soared 40.77%.
• Adma Biologics' Current Assets stood at $208.7 million in 2021, then rose by 29.55% to $270.4 million in 2022, then dropped by 4.95% to $257.0 million in 2023, then climbed by 28.95% to $331.4 million in 2024, then soared by 40.77% to $466.5 million in 2025.
• The last three Current Assets figures came in at $466.5 million (Q4 2025), $402.7 million (Q3 2025), and $399.6 million (Q2 2025), per Business Quant data.